DelayedPDUFA target action date

Molbreevi (molgramostim)

Savara (SVRA)

Marketer take

Rare pulmonary launch; the review was already extended three months, so plan launch materials with date-slip contingency.

Sponsor company
Savara (SVRA)
Indication
Autoimmune pulmonary alveolar proteinosis (aPAP)
Therapeutic area
Pulmonology, Rare disease
Event
PDUFA target action date
Date
Nov 22, 2026
Status
Delayed
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move